{"entity":{"id":"nct07546500","kind":"trial","name":"A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression","aka":["ASPENOVA"],"tldr":"A phase 3 trial testing Azenosertib in ovarian cancer, now recruiting.","summary":"A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression is a phase 3 interventional study registered as NCT07546500, led by K-, Beta with European Network of Gynaecological Oncological Trial Groups (ENGOT) and GOG Foundation, and recruiting on the registry. Official title: A Randomised, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression. Planned enrolment is 420 participants (estimated). The study started in 2026-04-17 and primary completion is expected in 2028-05-31. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07546500","url":"https://clinicaltrials.gov/study/NCT07546500"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian","high-grade-serous-ovarian-cancer","platinum-resistant-ovarian-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["azenosertib"],"companies":["zentalis-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07546500","phase":"3","setting":"A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression","sponsor":"K-, Beta","started":"2026-04-17","startedType":"actual","enrolled":420,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07546500/","neighbours":{"cancer":[{"id":"high-grade-serous-ovarian-cancer","kind":"cancer","name":"High-grade serous ovarian cancer","route":"/cancers/high-grade-serous-ovarian-cancer/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"drug":[{"id":"azenosertib","kind":"drug","name":"Azenosertib","route":"/drugs/azenosertib/"}],"company":[{"id":"zentalis-pharmaceuticals","kind":"company","name":"Zentalis Pharmaceuticals","route":"/companies/zentalis-pharmaceuticals/"}]}}